Leave it to hedge fund manager Bill Ackman to turn one of his biggest investor-activism setbacks into one of his most bullish bets. Other than shorting Herbalife, the founder of Pershing Square Capital’s most high-profile play recently was his campaign last year to help drug maker Valeant